Life Care News
A Hope Of True Information

Fate Therapeutics to Present at Upcoming Investor


SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:

  • Cowen’s 6th Annual IO Next Summit available on demand on Friday, November 11, 2022 at 2:10 PM ET
  • Jefferies London Healthcare Conference on Wednesday, November 16, 2022 at 12:55 PM GMT, 7:55 AM ET, in London, United Kingdom
  • Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 12:00 PM ET in New York, New York

A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at The archived webcast will be available on the Company’s website shortly after the event.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit

Christina Tartaglia
Stern Investor Relations, Inc.

Get real time updates directly on you device, subscribe now.